Autolus Financial Statements From 2010 to 2024

AUTL Stock  USD 2.84  0.04  1.43%   
Autolus Therapeutics financial statements provide useful quarterly and yearly information to potential Autolus Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Autolus Therapeutics financial statements helps investors assess Autolus Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Autolus Therapeutics' valuation are summarized below:
Autolus Therapeutics does not presently have any fundamental signals for analysis.
Check Autolus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Autolus Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Autolus financial statements analysis is a perfect complement when working with Autolus Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Autolus Therapeutics Correlation against competitors.
For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.

Autolus Therapeutics Company Shares Outstanding Analysis

Autolus Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current Autolus Therapeutics Shares Outstanding

    
  266.12 M  
Most of Autolus Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Autolus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition

Based on the latest financial disclosure, Autolus Therapeutics has 266.12 M of shares currently outstending. This is 47.41% higher than that of the Biotechnology sector and 149.05% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 53.46% higher than that of the company.

Autolus Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Autolus Therapeutics's current stock value. Our valuation model uses many indicators to compare Autolus Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Autolus Therapeutics competition to find correlations between indicators driving Autolus Therapeutics's intrinsic value. More Info.
Autolus Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Autolus Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

About Autolus Therapeutics Financial Statements

Autolus Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Autolus Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. Autolus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 324 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Autolus Therapeutics is a strong investment it is important to analyze Autolus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Autolus Therapeutics' future performance. For an informed investment choice regarding Autolus Stock, refer to the following important reports:
Check out the analysis of Autolus Therapeutics Correlation against competitors.
For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.